These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33773987)

  • 21. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
    Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
    FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
    Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
    Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
    Jones AT; Narov K; Yang J; Sampson JR; Shen MH
    Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
    Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
    Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
    Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
    Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation.
    Alsaqati M; Heine VM; Harwood AJ
    Mol Autism; 2020 Oct; 11(1):80. PubMed ID: 33076974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.
    Li S; Takeuchi F; Wang JA; Fan Q; Komurasaki T; Billings EM; Pacheco-Rodriguez G; Moss J; Darling TN
    Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3539-44. PubMed ID: 18292222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
    Woodrum C; Nobil A; Dabora SL
    J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.
    Li S; Thangapazham RL; Wang JA; Rajesh S; Kao TC; Sperling L; Moss J; Darling TN
    Nat Commun; 2011; 2():235. PubMed ID: 21407201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of the Tuberous sclerosis complex 2 (TSC2) gene inhibits goat myoblasts proliferation and differentiation in understanding the underlying mechanism of muscle development.
    Lyu M; Shalitana A; Luo J; He H; Sun S; Wang P
    Gene; 2020 Oct; 757():144943. PubMed ID: 32652105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
    Inoki K; Li Y; Zhu T; Wu J; Guan KL
    Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.